Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,157 | 224 | 251 | 73 | 417 |
| TOTAL | $1,369 | $460 | $568 | $278 | $568 |
| Non-Current Assets | |||||
| PPE Net | 2 | 3 | 3 | 4 | 4 |
| Other Non-Current Assets | 103 | 115 | 127 | 138 | 150 |
| TOTAL | $105 | $117 | $130 | $142 | $154 |
| Total Assets | $1,474 | $578 | $698 | $420 | $722 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 1,510 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 932 | 815 | 716 | 1,178 | 1,311 |
| Accrued Expenses | 164 | 158 | 144 | 142 | 148 |
| TOTAL | $7,707 | $7,242 | $6,897 | $6,472 | $6,493 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | 24 | 24 | N/A |
| Other Non-Current Liabilities | 60 | 77 | 82 | 104 | 142 |
| TOTAL | $54 | $67 | $103 | $115 | $104 |
| Total Liabilities | $7,761 | $7,308 | $7,000 | $6,587 | $6,597 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 420,280 | 420,280 | 420,280 | 420,280 | 420,280 |
| Common Shares | 420 | 420 | 420 | 420 | 420 |
| Retained earnings | -265,127 | -264,144 | -262,854 | -261,689 | -260,378 |
| Other shareholders' equity | -71 | -51 | -63 | -62 | -50 |
| TOTAL | $-6,288 | $-6,731 | $-6,303 | $-6,167 | $-5,875 |
| Total Liabilities And Equity | $1,474 | $578 | $698 | $420 | $722 |